StockData
Solventum Corp logo

Solventum Corp (SOLV) stock

SOLVNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 14/3056% below fair value
$81.33−2.23 (-2.67%)

Close on Oct 30, 2026Market cap $13.84BP/E 9.9Yield –

Earnings

Solventum's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Nov 5, 2026
Q3 FY2026 · estimated, during market hours
Revenue, Q2 FY2026
$2.20B
0.0% on a year earlier
adjusted diluted earnings per share, Q2 FY2026
$2.55
$1.69 a year earlier
Latest guidance
Raised
Aug 5, 2026 · 3 items

Quarterly results

Revenue and earnings per share from each of Solventum's earnings releases, newest first

QuarterReportedRevenueYoYEPSAdj. EPSSource
Q3 FY2026ended Sep 30, 2026Nov 5, 2026Expected–––––
Q2 FY2026ended Jun 30, 2026Aug 5, 2026during market hours$2.20B0.0%$0.53$2.55Release
Q1 FY2026ended Mar 31, 2026May 5, 2026during market hours––––Release
Q4 FY2025ended Dec 31, 2025Feb 26, 2026during market hours$2.00B-3.6%$0.36$1.57Release
Q3 FY2025ended Sep 30, 2025Nov 6, 2025during market hours$2.10B+0.9%$7.22$1.50Release
Q2 FY2025ended Jun 30, 2025Aug 7, 2025during market hours$2.20B+5.7%$0.51$1.69Release
Q1 FY2025ended Mar 31, 2025May 8, 2025during market hours$2.10B+4.2%$0.78$1.34Release
Q4 FY2024ended Dec 31, 2024Feb 27, 2025during market hours$2.07B–$0.17$1.41Release
Q3 FY2024ended Sep 30, 2024Nov 7, 2024during market hours$2.08B–$0.70$1.64Release
Q2 FY2024ended Jun 30, 2024Aug 8, 2024during market hours$2.08B–$0.51$1.56Release
Q1 FY2024ended Mar 31, 2024May 9, 2024before the open$2.02B–$1.37$2.08Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Solventum's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
organic sales growthnon-GAAPFY2026+2.5% – +3%+2% – +3%RaisedAug 5, 2026
adjusted EPSnon-GAAPFY2026$7.10 – $7.20$6.40 – $6.60RaisedAug 5, 2026
free cash flownon-GAAPFY2026$200.00M – $300.00M$200.00MRaisedAug 5, 2026

Guidance vs results

The last range Solventum gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
FY2025adjusted EPS$5.98 – $6.08$6.10Σ4QAbove range

Guidance history

Every forecast Solventum put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Aug 5, 2026adjusted EPSFY2026$7.10 – $7.20Raised
Aug 5, 2026free cash flowFY2026$200.00M – $300.00MRaised
Aug 5, 2026organic sales growthFY2026+2.5% – +3%Raised
May 5, 2026Adjusted EPSFY2026$6.40 – $6.60Reaffirmed
May 5, 2026Free cash flowFY2026$200.00MReaffirmed
May 5, 2026Organic sales growthFY2026+2% – +3%Reaffirmed
Feb 26, 2026Adjusted EPSFY2026$6.40 – $6.60New
Feb 26, 2026Free cash flowFY2026$200.00MNew
Feb 26, 2026Organic sales growthFY2026+2% – +3%New
Nov 6, 2025organic sales growthFY2025+2% – +3%New
Nov 6, 2025adjusted EPSFY2025$5.98 – $6.08Raised
Nov 6, 2025free cash flowFY2025$150.00M – $250.00MLowered
Aug 7, 2025adjusted EPSFY2025$5.80 – $5.95New
Aug 7, 2025Free cash flowFY2025$450.00M – $550.00MNew
Aug 7, 2025organic sales growthFY2025+2% – +3%New
May 8, 2025Adjusted EPSFY2025$5.45 – $5.65Reaffirmed
May 8, 2025Free cash flowFY2025$450.00M – $550.00MReaffirmed
May 8, 2025Organic sales growthFY2025+1.5% – +2.5%Raised
Feb 27, 2025Adjusted EPSFY2025$5.45 – $5.65New
Feb 27, 2025Free cash flowFY2025$450.00M – $550.00MNew

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Solventum filed with the SEC as exhibits to Form 8-K or 6-K

  1. Solventum Reports Second Quarter 2026 Financial Results
    Results
  2. Solventum Announces Intent to Separate its Health Information Systems Business
    Update
  3. N THE COURT OF CHANCERY OF THE STATE OF DELAWARE
    News
  4. Solventum Reports First Quarter 2026 Financial Results
    Results
  5. Solventum Reports Fourth Quarter 2025 Financial Results and Introduces 2026 Full-Year Guidance
    Results
  6. Reflections on a year of growth and transformation
    Update
  7. Solventum Reports Third Quarter 2025 Financial Results
    Results
  8. Solventum Announces Early Tender Results and Upsizing of its Note Tender Offers
    News
  9. Solventum Announces Pricing of its Upsized $2 Billion Note Tender Offers
    News
  10. Solventum Completes Sale of its Purification & Filtration Business
    Update
  11. Solventum Announces $1.75 Billion Note Tender Offers
    News
  12. Solventum Announces Pricing of Secondary Offering of Common Stock
    News
  13. Unaudited Pro Forma Condensed Consolidated Financial Statements
    Update
  14. Solventum Reports Second Quarter 2025 Financial Results
    Results
  15. Solventum Reports First Quarter 2025 Financial Results
    Results